Close Menu

NEW YORK (GenomeWeb) – Thermo Fisher Scientific has signed agreements with Daiichi Sankyo and Takeda Pharmaceuticals to use its Oncomine Dx Target Test in clinical trials and drug development programs.

Under the terms of those partnerships, Thermo will validate additional biomarkers and gene variants on Oncomine and retain global commercialization rights for the test. The company will also be responsible for filing supplemental premarket approval applications with the US Food and Drug Administration.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Sep
30
Sponsored by
LGC SeraCare Life Sciences

Non-invasive prenatal testing (NIPT) continues to expand globally to support maternal-fetal patient care. 

Oct
09
Sponsored by
PerkinElmer

As cases of COVID-19 continued to grow this spring and summer in the US, so too did the number of Emergency Use Authorizations from the FDA for clinical diagnostic tests aimed at detecting current and past infections.